Drug profile

The FDA adverse-event record for Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
23.1%
death-coded share
Dog
most-reported species
3
Not eating - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
3
Deaths Reported
23.1%
Death Rate

Active Ingredients

Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane

Administration Routes

UnknownOral

Species Affected

Dog 13

Most Affected Breeds

Retriever - Labrador 3
Retriever - Golden 2
Beagle 2
Collie - Border 1
Terrier (unspecified) 1
Terrier - Rat 1
Terrier - Jack Russell 1
Shiba Inu 1
Boxer (German Boxer) 1

Most Reported Reactions

Not eating 3
Unsteady gait 2
Lack of efficacy - NOS 2
Vomiting 2
Shaking 2
Lethargy (see also Central nervous system depression in Neurological) 2
Bloody diarrhoea 2
Lack of efficacy (bacteria) - Borrelia 2
Dental disease 2
Other abnormal test result NOS 2
Increased weight 2
Death by euthanasia 2

Outcome Breakdown

Ongoing
4 (30.8%)
Recovered/Normal
3 (23.1%)
Outcome Unknown
3 (23.1%)
Euthanized
2 (15.4%)
Died
1 (7.7%)

Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane Adverse Event Insights

13 reports name Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane; 3 recorded a death outcome (23.1% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Hcl + Chondroitin Sulfate + Methylsulfonylmethane. Administration routes: Unknown, Oral.

By species: Dog (13 reports). By breed: Retriever - Labrador (3), Retriever - Golden (2), Beagle (2).

Leading clinical signs: Not eating (3), Unsteady gait (2), Lack of efficacy - NOS (2), Vomiting (2). Outcome, 13 coded reports: Ongoing leads at 30.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.